We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A pilot study on feasibility, toxicity and efficacy of novel hypofractionated radiation therapy in advanced nonnasopharyngeal head and neck carcinoma treated with palliative intent.
- Authors
Meyur, Suman; Pal, Suparna Kanti; Maiti, Sumana; Basu, Siddhartha
- Abstract
Introduction: For palliative treatment in patients with advanced inoperable stage IV head and neck cancer hypofractionated radiotherapy is an efficient, cost-effective option, providing a logistic advantage. Though there are multiple regimens prescribed, no standard of care has been confirmed. In this study, a novel hypofractionated regimen has been tested for feasibility and toxicity along with an assessment of objective treatment response and survival along with self-reported quality of life. Patients and methods: 30 Patients, having pathologically proven advanced and metastatic non-nasopharyngeal squamous cell carcinoma of Head and Neck (Stage IV) attending the Radiotherapy Department of Hospital were allocated to the prescribed hypofractionation regime with 35 Gray in 7 fractions, given as 2 days a week (total 3.5 weeks). In patients with good response and tolerability, 10 Gray boosts in 2 fractions were given. Patients were followed up at regular intervals for at least 1 year. Results: The regimen faced a 97% treatment completion rate. Mean time to completion (from first contact) is 5.8 (95% CI = 5.7–6.0) weeks. The toxicity of this treatment regimen was tolerable with 23.3% acute and 33.3% incidence of chronic grade 3/4 toxicities. Objective response rate of this study was 66.7% (p = 0.001) with further 16.7% patients having stable disease. After one month of treatment significant improvement of quality of life was reported in terms of global health score, functional score and symptoms score. Mean progression-free survival is 34.4 (95% CI = 27.8–41.1) weeks with 49.4 (95% CI = 44.3–54.5) weeks of overall survival in 1 year follow up period. Conclusions: The regimen is well tolerated and is highly feasible and has provided a good response rate
- Subjects
PALLIATIVE treatment; TOXICITY testing; RADIOTHERAPY; NASOPHARYNX cancer; DRUG efficacy
- Publication
Palliative Medicine in Practice, 2021, Vol 15, Issue 4, p289
- ISSN
2545-0425
- Publication type
Article
- DOI
10.5603/PMPI.2021.0022